{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T01:07:45Z","timestamp":1792976865755,"version":"4.5.0"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002794","name":"Swedish Cancer Society","doi-asserted-by":"publisher","award":["22 2054 Pj 01 H"],"award-info":[{"award-number":["22 2054 Pj 01 H"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Total neoadjuvant treatment (TNT) results in more complete responses and less risk of distant metastasis (DM) compared with chemoradiotherapy in locally advanced rectal cancer (LARC). The best schedule and the most suitable patients are unknown. In Sweden, after the closure of the RAPIDO trial, all hospitals in five out of six healthcare regions treated LARC patients with an abbreviated RAPIDO schedule, LARCT-US. Long-term data are reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Between July 2016 and June 2020, LARC patients with at least one high-risk criterion for recurrence according to staging MRI (cT4, cN2, mesorectal fascia involvement &amp;lt;1\u2005mm, extramural vascular involvement, lateral node involvement) received TNT consisting of 5 \u00d7 5\u2005Gy followed by four cycles of CAPOX\/six cycles of FOLFOX.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Curatively treated patients (437 of 462) were analysed after a median of 6.5 (interquartile range 5.9\u20137.2)\u2005years of follow-up. cT4 was seen in 53.5%. Sixty-two patients with a cCR entered a watch-and-wait programme (21 patients with regrowth) and 375 patients underwent primary surgery. At 5\u2005years, of the 437 patients, locoregional recurrence (LRR) occurred in 26 patients (5.9% (95% c.i. 3.7% to 8.2%)) and DM occurred in 108 patients (24.7% (95% c.i. 20.7% to 28.7%)). The distal resection margin was \u226410\u2005mm in 8.3% of patients after a sphincter-saving procedure (a lower percentage than in RAPIDO). The 109 patients (24.9%) with a complete response (48 patients with a cCR sustained for &amp;gt;1\u2005year after the start of radiotherapy and 61 patients with a pCR) had excellent outcomes (0% with LRR and 3.7% with DM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>TNT consisting of 5 \u00d7 5\u2005Gy followed by four cycles of CAPOX\/six cycles of FOLFOX resulted in excellent locoregional and distant control, despite inclusion of more advanced tumours than previous TNT studies. The low LRR risk in LARCT-US could be explained by more adequate distal resection margins practiced at Swedish centres.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/bjs\/znag014","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T06:17:21Z","timestamp":1771481841000},"source":"Crossref","is-referenced-by-count":5,"title":["Locoregional and systemic control after total neoadjuvant therapy with short-course radiotherapy for locally advanced rectal cancer: long-term outcomes from the LARCT-US study"],"prefix":"10.1093","volume":"113","author":[{"given":"Israa","family":"Imam","sequence":"first","affiliation":[{"name":"Department of Immunology, Genetics and Pathology, Uppsala University , Uppsala ,","place":["Sweden"]},{"name":"Department of Oncology, Akademiska Sjukhuset , Uppsala ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0438-5887","authenticated-orcid":false,"given":"Per J","family":"Nilsson","sequence":"additional","affiliation":[{"name":"Department of Pelvic Cancer, Division of Coloproctology, Karolinska University Hospital , Stockholm ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanweera","family":"Khan","sequence":"additional","affiliation":[{"name":"Department of Immunology, Genetics and Pathology, Uppsala University , Uppsala ,","place":["Sweden"]},{"name":"Department of Oncology, Akademiska Sjukhuset , Uppsala ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9966-4904","authenticated-orcid":false,"given":"Eva","family":"Angenete","sequence":"additional","affiliation":[{"name":"Department of Surgery, SSORG\u2014Scandinavian Surgical Outcomes Research Group, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg , Gothenburg ,","place":["Sweden"]},{"name":"Department of Surgery, Region V\u00e4stra G\u00f6taland, Sahlgrenska University Hospital , Gothenburg ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bengt","family":"Glimelius","sequence":"additional","affiliation":[{"name":"Department of Immunology, Genetics and Pathology, Uppsala University , Uppsala ,","place":["Sweden"]},{"name":"Department of Oncology, Akademiska Sjukhuset , Uppsala ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,19]]},"reference":[{"key":"2026041616415917800_znag014-B1","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1093\/annonc\/mdw668","article-title":"Adding extra dimensions in rectal cancer theory","volume":"28","author":"Glynne-Jones","year":"2017","journal-title":"Ann Oncol"},{"key":"2026041616415917800_znag014-B2","doi-asserted-by":"crossref","first-page":"e10537","DOI":"10.48101\/ujms.v129.10537","article-title":"Recent advances in rectal cancer treatment\u2014are we on the right track?","volume":"129","author":"Glimelius","year":"2024","journal-title":"Ups J Med Sci"},{"key":"2026041616415917800_znag014-B3","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1093\/annonc\/mdz186","article-title":"Long-course preoperative chemoradiation versus 5 \u00d7 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: long-term results of the randomized Polish II study","volume":"30","author":"Cisel","year":"2019","journal-title":"Ann Oncol"},{"key":"2026041616415917800_znag014-B4","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(20)30555-6","article-title":"Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial","volume":"22","author":"Bahadoer","year":"2021","journal-title":"Lancet Oncol"},{"key":"2026041616415917800_znag014-B5","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1200\/JCO.21.01667","article-title":"Multicenter, randomized, phase III trial of short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR)","volume":"40","author":"Jin","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026041616415917800_znag014-B6","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S1470-2045(21)00079-6","article-title":"Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial","volume":"22","author":"Conroy","year":"2021","journal-title":"Lancet Oncol"},{"key":"2026041616415917800_znag014-B7","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1001\/jamaoncol.2025.2026","article-title":"Total neoadjuvant therapy for locally advanced rectal cancer","volume":"11","author":"Audisio","year":"2025","journal-title":"JAMA Oncol"},{"key":"2026041616415917800_znag014-B8","doi-asserted-by":"crossref","first-page":"e766","DOI":"10.1097\/SLA.0000000000005799","article-title":"Locoregional failure during and after short-course radiotherapy followed by chemotherapy and surgery compared to long-course chemoradiotherapy and surgery\u2014a five-year follow-up of the RAPIDO trial","volume":"278","author":"Dijkstra","year":"2023","journal-title":"Ann Surg"},{"key":"2026041616415917800_znag014-B9","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.annonc.2024.06.019","article-title":"Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial","volume":"35","author":"Conroy","year":"2024","journal-title":"Ann Oncol"},{"key":"2026041616415917800_znag014-B10","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1056\/NEJMoa1713709","article-title":"Duration of adjuvant chemotherapy for stage III colon cancer","volume":"378","author":"Grothey","year":"2018","journal-title":"N Engl J Med"},{"key":"2026041616415917800_znag014-B11","doi-asserted-by":"crossref","first-page":"102771","DOI":"10.1016\/j.eclinm.2024.102771","article-title":"Total neoadjuvant treatment using short-course radiotherapy and four CAPOX cycles in locally advanced rectal cancer with high-risk criteria for recurrence: a Swedish nationwide cohort study (LARCT-US)","volume":"75","author":"Glimelius","year":"2024","journal-title":"EClinicalMedicine"},{"key":"2026041616415917800_znag014-B12","doi-asserted-by":"crossref","first-page":"zrae151","DOI":"10.1093\/bjsopen\/zrae151","article-title":"Short-term outcomes from the \u2018Watch and Wait\u2019 (WoW) study: prospective cohort study","volume":"9","author":"Rydbeck","year":"2025","journal-title":"BJS Open"},{"key":"2026041616415917800_znag014-B13","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/biomet\/80.1.27","article-title":"Bias reduction of maximum likelihood estimates","volume":"80","author":"Firth","year":"1993","journal-title":"Biometrika"},{"key":"2026041616415917800_znag014-B14","doi-asserted-by":"crossref","first-page":"znaf190","DOI":"10.1093\/bjs\/znaf190","article-title":"Factors influencing locoregional recurrence rates in locally advanced rectal cancer after total neoadjuvant treatment versus chemoradiotherapy in the RAPIDO trial","volume":"112","author":"Prata","year":"2025","journal-title":"Br J Surg"},{"key":"2026041616415917800_znag014-B15","doi-asserted-by":"crossref","first-page":"101964","DOI":"10.1016\/j.ctrv.2020.101964","article-title":"How to measure tumour response in rectal cancer? An explanation of discrepancies and suggestions for improvement","volume":"84","author":"Nagtegaal","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"2026041616415917800_znag014-B16","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1245\/s10434-011-2035-2","article-title":"Is the 1-cm rule of distal bowel resection margin in rectal cancer based on clinical evidence? A systematic review","volume":"19","author":"Bujko","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"2026041616415917800_znag014-B17","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1007\/s13193-022-01565-z","article-title":"The impact of narrow and infiltrated distal margin after proctectomy for rectal cancer on patients\u2019 outcomes: a systematic review and meta-analysis","volume":"13","author":"Metwally","year":"2022","journal-title":"Indian J Surg Oncol"},{"key":"2026041616415917800_znag014-B18","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2023.02.027","article-title":"Risk and location of distant metastases in patients with locally advanced rectal cancer after total neoadjuvant treatment or chemoradiotherapy in the RAPIDO trial","volume":"185","author":"Bahadoer","year":"2023","journal-title":"Eur J Cancer"},{"key":"2026041616415917800_znag014-B19","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/ijc.34880","article-title":"Clinical and genetic factors associated with tumor response to neoadjuvant (chemo)radiotherapy, survival and recurrence risk in rectal cancer","volume":"155","author":"Hammarstr\u00f6m","year":"2024","journal-title":"Int J Cancer"},{"key":"2026041616415917800_znag014-B20","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1080\/0284186X.2022.2122866","article-title":"The importance of measuring baseline tumour volume (or alternatively tumour length along with its rectal circumferential extent) in the watch-and-wait strategy in rectal cancer: a review","volume":"61","author":"Ho\u0142dakowska","year":"2022","journal-title":"Acta Oncol"},{"key":"2026041616415917800_znag014-B21","doi-asserted-by":"crossref","first-page":"5570","DOI":"10.1245\/s10434-024-15552-x","article-title":"Risk factors for recurrence after surgery for rectal cancer in a modern, nationwide population-based cohort","volume":"31","author":"Doroudian","year":"2024","journal-title":"Ann Surg Oncol"},{"key":"2026041616415917800_znag014-B22","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1200\/JCO.2010.33.1595","article-title":"Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials","volume":"29","author":"Valentini","year":"2011","journal-title":"J Clin Oncol"},{"key":"2026041616415917800_znag014-B23","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.radonc.2021.01.002","article-title":"Neoadjuvant rectal (NAR) score: value evaluating the efficacy of neoadjuvant therapy and prognostic significance after surgery?","volume":"157","author":"Imam","year":"2021","journal-title":"Radiother Oncol"}],"container-title":["British Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjs\/advance-article-pdf\/doi\/10.1093\/bjs\/znag014\/66982831\/znag014.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjs\/article-pdf\/113\/3\/znag014\/66982831\/znag014.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjs\/article-pdf\/113\/3\/znag014\/66982831\/znag014.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T20:42:13Z","timestamp":1776372133000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjs\/article\/doi\/10.1093\/bjs\/znag014\/8490042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,19]]},"references-count":23,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,2,19]]},"published-print":{"date-parts":[[2026,3,4]]}},"URL":"https:\/\/doi.org\/10.1093\/bjs\/znag014","relation":{},"ISSN":["0007-1323","1365-2168"],"issn-type":[{"value":"0007-1323","type":"print"},{"value":"1365-2168","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2026,2,19]]},"article-number":"znag014"}}